-4%

est. 2Y upside i

HealthcareSeries A

Apothékary started with our founder, Shizu Okusa, and her family’s traditional Japanese approach to healing — using nature as medicine instead of over-the-counter fixes. In many Eastern cultures, traditional medicine in the form of plants and herb has been used for centuries to address the root cause of common ailments.

Rank

#2401

Sector

Wellness

Est. Liquidity

~2Y

Data Quality

Data: Medium

With an expected downside of ~4% over 2 years, the equity offer from Apothékary is high-risk and likely negative on a risk-adjusted basis.

Last updated: July 3, 2026

Bull (10%)+145%

IPO window opens or category leadership drives multiple to 4x revenue. Exit at $212M, net of 20% dilution yields 145% upside.

Base (45%)+13%

Multiple converges to ~2x revenue, exit at $106M. After 20% dilution, upside is 12.5%.

Bear (45%)-54%

Multiple compresses to 1x revenue, exit at $53M. After 20% dilution, loss of 53.75%. Preference stack does not trigger as exit > $32M.

Est. time to liquidity~2.0 years

Preference Stack Risk

severe

Funding Intensity

91%

$32M total funding represents 40% of entry valuation ($80M), creating a large preference overhang for common stock.

Dilution Risk

high

Current cash likely supports 12-18 months; another capital raise within 24 months is expected, diluting existing holders by 15-25%.

Secondary Liquidity

none

No secondary market trades reported; liquidity only via acquisition or IPO.

Questions to Ask at the Interview

Strategic questions based on Apothékary's data — designed to show you've done your homework.

  • 1

    “How does Apothékary plan to defend against deep-pocketed incumbents like Unilever and Thorne?”

  • 2

    “What is the path to profitability, and what unit economics are being targeted?”

  • 3

    “Given the private stage, what is the expected timeline to liquidity, and are there any secondary sale programs?”

Community

Valuation Sentiment

Our model estimates -4% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.